Oxysterols and neurodegenerative diseases

被引:235
|
作者
Bjorkhem, Ingemar [1 ]
Cedazo-Minguez, Angel [2 ]
Leoni, Valerio [3 ]
Meaney, Steve [4 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Huddinge 14186, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Huddinge 14186, Sweden
[3] C Besta Neurol Inst, Div Biochem & Genet, Milan, Italy
[4] Dublin Inst Technol, Fac Sci, Sch Biol Sci, Dublin, Ireland
关键词
Blood-brain barrier; 24S-Hydroxycholesterol; 27-Hydroxycholesterol; beta-Amyloid; Activity regulated cytoskeleton-associated protein; CYP27; CYP46; CHOLESTEROL-BIOSYNTHESIS PATHWAY; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; MULTIPLE-SCLEROSIS; PLASMA-LEVELS; 24S-HYDROXYCHOLESTEROL CEREBROSTEROL; CYTOCHROME-P450; 46A1; HUNTINGTONS-DISEASE;
D O I
10.1016/j.mam.2009.02.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In contrast to their parent molecule cholesterol, two of its side-chain oxidized metabolites are able to cross the blood-brain barrier. There is a concentration-driven flux of 24S-hydroxycholesterol (245-OHC) from the brain into the circulation, which is of major importance for elimination of excess cholesterol from the brain. The opposite flux of 27-hydroxycholesterol (27-OHC) from the circulation into the brain may regulate a number of key enzymes within the brain. In vitro experiments suggest that the balance between the levels of these two molecules may be of importance for the generation of beta-amyloid peptides. In primary cultures of rat hippocampal cells 27-OHC is able to suppress expression of the activity regulated cytoskeleton-associated protein (Arc), a protein important in memory consolidation which is reduced in patients with Alzheimer's disease (AD). In the present work we explore the possibility that the flux of 27-OHC from the circulation into the brain represents the missing link between AD and hypercholesterolemia, and discuss the possibility that modification of this flux may be a therapeutic strategy. Lastly, we discuss the use of oxysterols as diagnostic markets in neurodegenerative disease. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 50 条
  • [1] Oxysterols as biomarkers in neurodegenerative diseases
    Leoni, Valerio
    Caccia, Claudio
    CHEMISTRY AND PHYSICS OF LIPIDS, 2011, 164 (06) : 515 - 524
  • [2] Microorganisms' Footprint in Neurodegenerative Diseases
    Dehhaghi, Mona
    Panahi, Hamed Kazemi Shariat
    Guillemin, Gilles J.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
  • [3] The complement system in neurodegenerative diseases
    Nimmo, Jacqui
    Byrne, Robert A. J.
    Daskoulidou, Nikoleta
    Watkins, Lewis M.
    Carpanini, Sarah M.
    Zelek, Wioleta M.
    Morgan, B. Paul
    CLINICAL SCIENCE, 2024, 138 (06) : 387 - 412
  • [4] Oxysterols as a biomarker in diseases
    Zmyslowski, Adam
    Szterk, Arkadiusz
    CLINICA CHIMICA ACTA, 2019, 491 : 103 - 113
  • [5] Nitric oxide neurotoxicity in neurodegenerative diseases
    Boje, KMK
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 763 - 776
  • [6] The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases
    Cannon, Jason R.
    Greenamyre, J. Timothy
    TOXICOLOGICAL SCIENCES, 2011, 124 (02) : 225 - +
  • [7] Dendrimers in Neurodegenerative Diseases
    Perez-Carrion, Maria Dolores
    Posadas, Inmaculada
    PROCESSES, 2023, 11 (02)
  • [8] Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases
    Fakhoury, Marc
    NEURODEGENERATIVE DISEASES, 2015, 15 (02) : 63 - 69
  • [9] Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
    Vasincu, Alexandru
    Rusu, Razvan-Nicolae
    Ababei, Daniela-Carmen
    Larion, Madalina
    Bild, Walther
    Stanciu, Gabriela Dumitrita
    Solcan, Carmen
    Bild, Veronica
    BIOLOGY-BASEL, 2022, 11 (03):
  • [10] Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
    Barchet, Thomas M.
    Amiji, Mansoor M.
    EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (03) : 211 - 225